Jefferies resumed coverage on Viridian Therapeutics with a new price target
$VRDN
Medical Specialities
Health Care
Jefferies resumed coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $44.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/25/2025 | $44.00 | Buy | Jefferies |
| 12/19/2024 | $37.00 → $27.00 | Overweight → Equal Weight | Wells Fargo |
| 11/25/2024 | Buy | TD Cowen | |
| 9/11/2024 | $30.00 → $38.00 | Buy | Needham |
| 6/11/2024 | $29.00 | Outperform | Wolfe Research |
| 6/6/2024 | $23.00 | Buy | Goldman |
| 5/9/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 5/9/2024 | $25.00 → $20.00 | Buy → Neutral | B. Riley Securities |
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and Series B non-voting convertible preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series B preferred stock will be convertible into 66.67 shares of common stock at the election of the holder, subject to b
–Third synthetic royalty transaction & second pre-approval deal for DRI –– Further increases portfolio exposure to rare diseases –– Long-dated cashflows, extend portfolio duration –– DRI Healthcare to pay US$55 million upfront; up to US$300 million total investment, subject to achievement of certain milestones– TORONTO, Oct. 20, 2025 /CNW/ - DRI Healthcare Trust (TSX:DHT) (TSX:DHT) ("DRI Healthcare"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a royalty interest in the U.S. net sales of veligrotug (formerly known as VRDN-001) and VRDN-003 from Viridian Therapeutics, Inc. (NASDAQ:VRDN) for an aggregate purchase price of up to US$3
- Viridian receives $55 million upfront and potential near-term milestones up to $115 million based on positive VRDN-003 topline data and U.S. veligrotug marketing approval - - Upfront and anticipated near-term milestones together with existing cash expected to fully fund the commercial launches of both veligrotug and VRDN-003 - - Veligrotug Biologics License Application (BLA) submission expected imminently; VRDN-003 phase 3 clinical trial topline data readouts now expected Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 - - Amended credit facility with Hercules Capital, Inc., providing additional access to capital at the company's discretion based on milestone achievements - Viridian
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
Jefferies resumed coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $44.00
Wells Fargo downgraded Viridian Therapeutics from Overweight to Equal Weight and set a new price target of $27.00 from $37.00 previously
TD Cowen initiated coverage of Viridian Therapeutics with a rating of Buy
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye disease (TED), are on track for topline data in the first half of 2026 - - VRDN-006 clinical data in healthy volunteers on track for third quarter 2025 - - VRDN-008, a bispecific neonatal Fc receptor (FcRn) inhibitor with an extended half-life, on track for an Investigational New Drug (IND) submission for year-end 2025 - - Appointed Jeff Ajer, long-time Chief Commercial Officer of BioMarin, to Viridian's Board
- Mr. Ajer was most recently Chief Commercial Officer at BioMarin - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement, and sales operations. He most recently served as the Executive Vice President and Chief Commercial Officer (CCO) at BioMarin Pharmaceutical, where he joined in 20
- Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing Q4W or Q8W subcutaneous (SC) VRDN-003 in active and chronic TED, progressing as planned and on track for topline data for both trials in the first half of 2026 - - Proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter o
- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global phase 3 study in patients with chronic TED to demonstrate a statistically significant and clinically meaningful 56% diplopia responder rate (placebo-adjusted rate of 31%, p = 0.0006) and 32% rate of diplopia complete resolution (placebo-adjusted rate of 18%, p = 0.0152) - - Veligrotug was generally well-tolerated with 94% of patients completing their treatment course and a 9.6% placebo-adjusted rate of hearing impairment - - BLA submission for veligrotug
- THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presenta
- Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of 70% and a placebo-adjusted PRR of 64% (p < 0.0001) - - All secondary endpoints were highly statistically significant (p < 0.0001), with clinically meaningful patient outcomes, including complete resolution of diplopia in 54% of patients (placebo-adjusted rate of 43%) and reduction of Clinical Activity Score (CAS) to 0 or 1 in 64% of patients (placebo-adjusted reduction of 46%) treated with veligrotug - - Veligrotug was generally well-tolerated with no treatment-r
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)